Genesis Healthcare Partners
  • Patient PortalContactNews
  • Call Toll-Free at 855.888.7701
  • About Genesis
    • Mission and Values
    • Genesis Careers
    • Quality & Safety
    • Contact Us
    • News
    • Medical Physics Residency Program
    • Site Map
  • Genesis Careers
  • Genesis Providers
  • Genesis Locations
    • Urology San Diego
      • Encinitas - Genesis Urology
      • Rancho Bernardo - Genesis Urology
      • La Jolla - Genesis Urology
      • Hillcrest - Genesis Urology
      • Kearny Mesa - Genesis Urology
      • La Mesa - Genesis Urology
      • Coronado - Genesis Urology
      • Chula Vista - Genesis Urology
    • Urology Greater Los Angeles
      • Greater Los Angeles - Torrance - Telo
      • Greater Los Angeles - Torrance - Earl
      • Greater Los Angeles - Sherman Oaks
      • Greater Los Angeles - Santa Clarita
      • Greater Los Angeles - Tarzana
    • Urology West Coast
      • West Coast Urology - Downey
      • West Coast Urology - Inglewood
      • West Coast Urology - Los Alamitos
      • West Coast Urology - PCU
      • West Coast Urology - Whittier
    • Radiation Oncology
      • Escondido - Radiation Oncology
      • San Diego - Radiation Oncology
    • Genesis Cyberknife
    • Gastroenterology
    • Genesis Prostate Cancer Center
    • Medical Research
      • Research San Diego
      • Research Greater Los Angeles
    • Laboratory Services
      • Laboratory San Diego
      • Laboratory Greater Los Angeles
    • Administrative Offices
  • My Health A - Z
  • Treatment Options
    • Urology Care
    • Radiation Oncology
    • Gastroenterology
    • Genesis Prostate Cancer Center
    • Robotics Program
    • Genesis CyberKnife
    • Women's Pelvic Care
    • Immunotherapy
    • Cryotherapy
    • Lithotripsy
    • Urolift® for BPH
    • Rezūm® for BPH
    • GreenLight™ Laser Therapy for BPH
    • Axonics Therapy for Bladder & Bowel
    • Acoustic Wave Therapy for ED
  • Diagnostic Services
    • Genesis Laboratory
    • Know Error® Biopsies
    • Prostate Cancer Screening
  • Patient Resources
    • Patient Portal
    • Make Payment
    • Patient Forms
    • Billing FAQs
    • Videos
    • Notice of Privacy Practices
  • Physician Resources
    • Genesis Research
    • CyberKnife Information for Physicians
    • Remote IT Assistance
Genesis Logo
  • In The News
    About Genesis
Home > About Genesis > News >
  • About Genesis
  • Mission & Values
  • Genesis Careers
  • Contact Us
  • Site Map
  • News

Accuray CyberKnife® System Provides Excellent Disease Control for Men with Recurrent Prostate Cancer, a Medical Condition with Few Viable Treatment Options

SUNNYVALE, Calif., Jan. 8, 2020

Accuray Incorporated (NASDAQ: ARAY) announced on January 8, data from a prospective study which showed that at five years, stereotactic body radiation therapy (SBRT) administered with the CyberKnife® System provided excellent disease control with low rates of toxicity in men with locally recurrent prostate cancer after previous treatment with radiation therapy. Importantly, 69 percent of men required no androgen deprivation therapy (ADT) treatment within the first five years following CyberKnife prostate SBRT. ADT, also known as "hormone therapy," is the most common treatment given for recurrent prostate cancer. However, its use is associated with unfortunate side effects including loss of libido, hot flashes, bone fractures, loss of muscle mass and physical strength, and weight gain1. The study was recently published online in the International Journal of Radiation Oncology*Biology*Physics.

Hypofractionated radiation therapy involves the delivery of higher doses of radiation over a smaller number of treatment sessions, compared to conventional radiation therapy which requires a substantially longer course of treatment. SBRT uses advanced techniques to deliver ultra-hypofractionated radiation therapy — very high doses of radiation are administered over several days. This treatment process necessitates an extremely high degree of accuracy and precision. The CyberKnife System, designed to deliver SBRT, is the only radiotherapy device that can maintain sub-millimetric accuracy with continual imaging and automatic beam delivery corrections, including rotation, throughout treatment delivery, making it easier for clinicians to effectively treat patients while minimizing dose to healthy tissue.

"Men diagnosed with recurrent prostate cancer after previous radiation therapy have few treatment choices. Most, if treated, receive only ADT which has the potential for long-lasting 'whole body' side effects while rarely eradicating the tumor completely," said Donald B. Fuller, M.D., at Genesis Healthcare Partners in San Diego, California and lead investigator of the study. "This study demonstrates that prostate SBRT delivered using the CyberKnife System offers a viable, non-invasive option for an underserved patient population and most typically delays the need for ADT for greater than five years, which would provide substantial quality of life benefits. From a technology viewpoint, the inherent sub-millimeter accuracy of the CyberKnife System due to its highly unique tracking method was critical to the success and safety of this protocol, allowing the dose to be delivered to the prostate with no additional expansion of the target volume."

Click here to learn about how Dr. Fuller uses the CyberKnife System in his practice.

Study Highlights

The study titled, "Retreatment for Local Recurrence of Prostatic Carcinoma After Prior Therapeutic Irradiation: Efficacy and Toxicity of HDR-Like SBRT," evaluated 50 patients with biopsy-proven recurrent prostate cancer diagnosed at least two years after initial treatment. Forty-three patients had previously received treatment with conventionally fractionated radiation therapy and seven patients had received treatment with another method (five brachytherapy, one SBRT and one radical prostatectomy followed by post-prostate bed salvage radiation therapy). This study demonstrated:

  • At five years, the disease-free survival (DFS) rate was 60 percent, indicating patients experienced no signs or symptoms of their cancer over that time period. This rate is within the reported range for salvage brachytherapy and comparable to reported salvage radical prostatectomy results, but without the need for hospitalization, anesthesia, and long recovery times typically associated with these treatments;
  • The median prostate specific antigen (PSA) decreased to 0.16 ng/mL at five years, similar to initial treatment with brachytherapy and lower than typical conventional fractionation, based on results from other studies;
  • No grade two or higher gastrointestinal (GI) events were reported. Genitourinary (GU) toxicity was lower than reported rates for salvage radical prostatectomy and seems less frequent after prior standard external radiation treatment.

"This study is significant because it highlights a potential new option for extending symptom-free survival in men with locally recurrent prostate cancer previously treated with radiation therapy," said Fabienne Hirigoyenberry-Lanson, Ph.D., vice president global medical and scientific affairs, at Accuray. "The data reinforces the benefits of the CyberKnife® System's robotic design and motion synchronization capabilities and show why CyberKnife prostate SBRT is becoming the treatment of choice by clinicians who want a high precision, versatile and non-invasive option that provides excellent disease control with minimal side effects."

SOURCE Accuray Incorporated

  • Related Topics
    • In the News
    • Donald B. Fuller, MD
    • Genesis Radiation Oncology
Share This Page
  • AboutCareersPatient ResourcesMedical Physics ResidencyPrivacySite map
  • Call Toll-Free at: 855.888.7701
  • © 2010 GENESIS HEALTHCARE PARTNERS, AN AFFILIATE OF UNIO HEALTH PARTNERS